Pharm of Drugs in Lower GI Flashcards
(25 cards)
2 classes of drugs that stimulate the ENS (for constipation)
Laxatives (bulk, osmotic, stimulant)
Opioid receptor antagonists
Bulk Laxatives
Introduction of indigestible, water absorbing molecules
Intestinal distention leading to ENS stimulation of peristalsis
Through dietary fiber or supplemental intake (methycellulose, psyllium husk)
Osmotic laxatives
Poorly absorbed salts that retain and/or draw water back into the colon via osmosis
Increased stimulation of peristalsis
Some may have additional effectiveness as stool softeners
Ex: salts and sugars, polyethelene glycol (know this name)
Side effects of osmotic laxatives
Electrolyte imbalance (salts only) Bloating and/or flatulence Abdominal cramps and/or diarrhea
Stimulant/Contact laxatives
Direct stimulation of myenteric plexus in ENS
Increases smooth muscle motility and evacuation of contents
Ex: sennosides, diphenylmethane
Side effects of Stimulant/Contact laxatives
Cramping and/or diarrhea
Pigmentation in colon (thought to be benign)
Should not take castor oil during pregnancy
Stool softeners
Increases surface lubrication of feces (possible penetration of liquid as well)
Soften fecal matter to reduce effort of excretion
Also known as emollients
Ex: glycerin, docusate
Opioid Receptor Antagonists
Selective competitive block of mu-opioid receptors
Prevent opioid-mediated stimulation of GI tract
Used for opioid-induced constipation
Ex: methylnaltrexone
Subcutaneous administration
Do not cross the BBB (peripherally selective effective) - no analgesic effect
Contraindications and side effects of opioid-receptor antagonists
Contraindicated in: Known or suspected GI blockage
Side effects: abdominal pain/cramping, diarrhea and/or flatulence, nausea
Opioid induced constipation line of therapies
Laxatives and stool softeners as first line
Progress to opioid receptor antagonists and/or Cl channel activators (lubiprostone)
Antimotility agents for diarrhea
Ex: loperamide (selective mu opioid receptor agonist)
Inhibition of ENS activity leading to increased colonic transport time and water absorption
Does not readily cross BBB (peripherally selective)
Does not appear to produce tolerance
Loperamide
Selective mu opioid receptor agonist
Used for acute non-infectious diarrhea or chronic diarrhea
Inhibition of ENS activity leading to increased colonic transport time and water absorption
Bismuth subsalicylate
Antisecretory effects
Reduction of intestinal prostaglandin production (reduced motility) and reduced Cl secretion (reduced liquidity)
Antimicrobial effects
Theory of treatment for IBS
Manage symptoms
Constipation, diarrhea, pain, bloating, cramping
Aminosalicylates
5-aminosalicylate Anti-inflammatory through a variety of possible mechanisms: NSAID-like inhibition of prostaglandins Interfere with cytokine porduction Reduced leukocyte activity
5-aminosalicylic acid
Acts topically at the site of diseased mucosa (systemic absorption and distribution not required)
A lot is absorbed, so there are formulations designed to increase drug exposure to distal small and the large intestine
For UC (induction and maintenance of remission)
Contraindications similar to aspirin (allergies, children under 2)
Mesalamine
Collective term for delayed release 5-ASA formulations
Side effects of 5-ASA
Nausea and/or GI upset Headaches Impaired folate absorption Hypersensitivity (rare) Inflammation of kidney (rare)
Glucocorticoids
For induction of remission in IBD
Ex: prednisone, prednisolone, or budesonide
Anti-inflammation through inhibition of chemokine/cytokine production, and inhibit transcription of several pro-inflammatory mediators
Side effects of glucocorticoids
PUD
Adrenal suppression
Fewer side effects with budesonide
Purine analogues
Immunosuppressants
Ex: azathioprine
Converted to guanine analogue that halts DNA/RNA synthesis
Somewhat selective for cells dividing rapidly, such as immune cells
For UC and Crohn’s
Methotrexate
Immunosuppressant
Inhibition of a key enzyme required for nucleotide synthesis (folate cant be produced)
Inhibition of cell proliferation unlikely at doses used in IBD treatment
For Crohn’s
Anti-TNFa therapy
Ex: infliximab
Monoclonal antibody against TNF
Prevents receptor activation that leads to inflammatory response
IV administration
Used for induction and maintenance of moderate to severe Crohns/UC, and the ones that are unresponsive to previous therapies
Side effects of Anti-TNFa therapy
Opportunistic infections
Hypersensitivity
Increased lymphoma risk